1
Country: USA | Funding: $614.6M
Neumora Therapeutics develops precision therapies for treatment of brain diseases. Its uses the propriety platform Precision Toolbox, which includes a suite of translational, medical and computational tools for information discovery, capable of applying precision medicine approaches. Its therapeutic portfolio includes seven programs for the treatment of neuropsychiatric disorders and neurodegenerative diseases (major depressive disorder, Alzheimer's disease, schizophrenia, and Parkinson's disease). Neumora's lead program, navacaprant, is a novel, highly selective kappa opioid receptor (KOR) antagonist nearing the end of development as a reliable monotherapy for the treatment of MDD. Navacaprant is an investigational, once-daily oral medication designed to modulate dopamine and reward signaling pathways, which play a critical role in the regulation of mood, cognition, reward and behavior.
Neumora Therapeutics develops precision therapies for treatment of brain diseases. Its uses the propriety platform Precision Toolbox, which includes a suite of translational, medical and computational tools for information discovery, capable of applying precision medicine approaches. Its therapeutic portfolio includes seven programs for the treatment of neuropsychiatric disorders and neurodegenerative diseases (major depressive disorder, Alzheimer's disease, schizophrenia, and Parkinson's disease). Neumora's lead program, navacaprant, is a novel, highly selective kappa opioid receptor (KOR) antagonist nearing the end of development as a reliable monotherapy for the treatment of MDD. Navacaprant is an investigational, once-daily oral medication designed to modulate dopamine and reward signaling pathways, which play a critical role in the regulation of mood, cognition, reward and behavior.
2
Country: USA | Funding: $487M
Cerebral is a mission-driven telemedicine company that provides affordable, efficient access to treatment for anxiety, depression and insomnia.
Cerebral is a mission-driven telemedicine company that provides affordable, efficient access to treatment for anxiety, depression and insomnia.
3
Country: USA | Funding: $466.5M
Spring uses AI to help patients with mental health problems feel better faster. The startup operates as an online mental health clinic for employers, using proprietary machine-learning technology to provide personalized treatment recommendations with hopes that they will be more effective.
Spring uses AI to help patients with mental health problems feel better faster. The startup operates as an online mental health clinic for employers, using proprietary machine-learning technology to provide personalized treatment recommendations with hopes that they will be more effective.
4
Country: USA | Funding: $451.4M
Neuronetics has pioneered and refined the NeuroStar TMS Therapy system. This non-invasive, non-systemic treatment for depression uses a highly focused, pulsed magnetic field to stimulate function in targeted brain regions. NeuroStar TMS Therapy is a safe and effective outpatient procedure, performed in a physician's office with each treatment lasting about 37 minutes daily for four to six weeks.
Neuronetics has pioneered and refined the NeuroStar TMS Therapy system. This non-invasive, non-systemic treatment for depression uses a highly focused, pulsed magnetic field to stimulate function in targeted brain regions. NeuroStar TMS Therapy is a safe and effective outpatient procedure, performed in a physician's office with each treatment lasting about 37 minutes daily for four to six weeks.
5
Country: UK | Funding: $421.2M
COMPASS Pathways is advancing the drug, the active ingredient in magic mushrooms, for use in people with treatment-resistant depression.
COMPASS Pathways is advancing the drug, the active ingredient in magic mushrooms, for use in people with treatment-resistant depression.
6
Country: USA | Funding: $325M
Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
7
Country: USA | Funding: $260M
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
8
Country: Australia | Funding: $140M
Draig Therapeutics is a clinical-stage depressive disorder biopharmaceutical startup.
Draig Therapeutics is a clinical-stage depressive disorder biopharmaceutical startup.
9
Country: USA | Funding: $102M
Midi is a virtual care clinic for women that treats depression, gynecological cancer, and period problems.
Midi is a virtual care clinic for women that treats depression, gynecological cancer, and period problems.
10
Country: Israel | Funding: $85.5M
Brainsway has revolutionized brain disorder treatment, with Brainsway Deep TMS therapy, or Deep Transcranial Magnetic Stimulation. With Brainsway Deep TMS, patients can regain wellbeing, calm and happiness in just a few weeks.
Brainsway has revolutionized brain disorder treatment, with Brainsway Deep TMS therapy, or Deep Transcranial Magnetic Stimulation. With Brainsway Deep TMS, patients can regain wellbeing, calm and happiness in just a few weeks.
11
Country: USA | Funding: $53.3M
Meru Health offers a digital program that helps improve the lives of people living with depression and saves on healthcare costs.
Meru Health offers a digital program that helps improve the lives of people living with depression and saves on healthcare costs.
12
Country: Germany | Funding: $37.5M
HMNC Brain Health is a precision medicine pioneer in psychiatry.
HMNC Brain Health is a precision medicine pioneer in psychiatry.
13
Country: Israel | Funding: $24M
Genetika+ is personalizing depression treatment for every individual.
Genetika+ is personalizing depression treatment for every individual.
14
Country: UK
Magstim has always been at the cutting edge of the evolution of transcranial magnetic stimulation (TMS) from its conception as a valuable research tool to its coming of age as a revolutionary treatment for nerve and brain disorders such as major depressive disorder (MDD).
Magstim has always been at the cutting edge of the evolution of transcranial magnetic stimulation (TMS) from its conception as a valuable research tool to its coming of age as a revolutionary treatment for nerve and brain disorders such as major depressive disorder (MDD).
15
Country: USA | Funding: $18.4M
NeuroSigma is a life sciences company focused on bioelectronics products and commercialization of its unique Trigeminal Nerve Stimulation (TNS) technology, and has a growing pipeline of treatments targeting epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Lennox Gastaut syndrome (LGS) and traumatic brain injury (TBI).
NeuroSigma is a life sciences company focused on bioelectronics products and commercialization of its unique Trigeminal Nerve Stimulation (TNS) technology, and has a growing pipeline of treatments targeting epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Lennox Gastaut syndrome (LGS) and traumatic brain injury (TBI).
16
Country: USA | Funding: $13.8M
Sentio is a behavioral health startup offering an emotion-sensing wearable Feel that provides continuous monitoring and real-time personalized interventions for individuals that suffer from anxiety and depression.
Sentio is a behavioral health startup offering an emotion-sensing wearable Feel that provides continuous monitoring and real-time personalized interventions for individuals that suffer from anxiety and depression.
17
Country: Sweden | Funding: $12.6M
Flow develops brain stimulation headset and therapy app to treat depression
Flow develops brain stimulation headset and therapy app to treat depression
18
Country: Sweden | Funding: $12.6M
Flow is the next wave of mental health treatment, combining brain stimulation and behaviour therapy in a unique programme to treat Major Depressive Disorder.
Flow is the next wave of mental health treatment, combining brain stimulation and behaviour therapy in a unique programme to treat Major Depressive Disorder.
19
Country: USA | Funding: $4.2M
Options MD provides personalized care for people suffering from severe and treatment-resistant mental illnesses.
Options MD provides personalized care for people suffering from severe and treatment-resistant mental illnesses.
